CGTX Stock — Cognition Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.04

Market cap

$98.9M

Cash

$34.0M

Enterprise value

$64.9M

Balance sheet

Cash	$34.0M
Debt	$0.0M
Net cash	$34.0M
Enterprise value	$64.9M
Basic shares	95.1M shares
Fully diluted shares	101.6M shares
Fully diluted market cap	$105.7M
Cash per share	$0.36

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CGTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 12 - Aug 23	CT1812	Phase 2	Early Alzheimer's Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Zervimesine

Phase 2 · Active Modality: oral small molecule

Aliases CT1812

Target S2R (sigma-2 receptor complex)

Partnerships Alzheimer's Clinical Trial Consortium (ACTC): collaboration on START trial; NIA grant funding ~$171M cumulative across programs ($81M START, $30.5M SHINE, $29.5M SHIMMER)

Indications

Alzheimer's disease (Phase 2)
Dementia with Lewy bodies (DLB) psychosis (Phase 2)
Geographic atrophy secondary to dry AMD (Phase 2)

Status note Lead product candidate. SHINE Phase 2 (mild-to-moderate AD) topline reported 2024; end-of-Phase 2 FDA meeting Jul 2025 concurred with Phase 3 plan (100 mg daily, >=6 months, low p-tau217 enrichment); START Phase 2 (545 MCI/early AD) enrollment concluded Dec 2025, topline after 18-month treatment completion. SHIMMER Phase 2 (DLB) topline Dec 2024; FDA aligned May 2026 on key aspects of pivotal DLB psychosis study (100 mg daily, 9 months). MAGNIFY Phase 2 in geographic atrophy voluntarily concluded Jan 2025 (~100 enrolled) to conserve resources.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CT1812
Lead indication	Early Alzheimer's Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05531656	Phase 2	Active, not recruiting	Sponsor	Cognition Therapeutics	—	Early Alzheimer's Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Cognition Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CGTX — Cognition Therapeutics Inc.